Life Sciences and Healthcare

Drive your research through data sharing and collaboration

The Children’s Tumor Foundation and Clarivate Analytics will host a live webinar to share insights from the CTF’s journey to find the cure for neurofibromatosis, a set of genetic disorders that causes tumors to grow along the nerves.

Strategic planning in a post-EHR industry

For most healthcare organizations, the looming shadow of an incoming EHR implementation has become a thing of the past. In fact, according to a report by the Office of the National Coordinator (ONC) for Health Information Technology, 96% of hospitals have a federally-tested and certified EHR. This comes after years in which many organizations within the […]

AMPs take aim at AMR as biopharma seeks new solutions to resistance

Antimicrobial resistance (AMR) is a topic that just won’t go away, and for good reason. Despite the plethora of threats facing humankind, including thousands of diseases in need of therapies or cures, many scientists worry that the biggest risk of extinction comes from the deadly pathogens that exist in uneasy cohabitation on planet Earth.

Reprocessing endoscopes: what is the true cost?

After investigations found hundreds of patients may have been exposed to antibiotic-resistant superbugs in procedures using a complex endoscope, several national standard-setting organizations updated their device reprocessing guidelines. The Society of Gastroenterology Nurses and Associates, Association of Perioperative Registered Nurses, and Association for the Advancement of Medical Instrumentation all issued new recommendations in areas including personal protective equipment (PPE), manual cleaning, visual […]

‘Open for Innovation’ outlines post-Brexit path

As the UK prepares to embark on a new path outside of the EU, writes Virginia Acha in the preface to a new look at the British pharma industry, it will need the best policies in place to foster a priority on innovation. “Open for Innovation: UK Biopharma R&D Sourcebook 2016” underscores the need for […]

Post-grant oppositions for pharma patents (Part 3): A look at potential strategies

In FY2016, the percentage of patents that were found to be valid in the PTAB’s final written decision for the biopharma sector was quite high (~34% valid vs. 39% invalid), relative to other industries (AIA Trial Statistics, https://www.uspto.gov/sites/default/files/documents/aia_statistics_november2016.pdf, accessed March 8, 2017). A well-planned strategy will help both a petitioner and patent owners (POs) maintain […]